tbuckley/cabot-search huggingface dataset:
NEURO-COGNITIVE
Authors: J. D. S. R. Gonzalez, O. Eduardo, A. Salvador, P. de la Mora Alejandra, A. M. Peiffer, C. M. Leyrer, D. Greene-Schloesser, W. T. Kearns, W. H. Hinson, S. B. Tatter, S. R. Rapp, M. E. Robbins, E. G. Shaw, M. D. Chan, M. de Groot, L. Douw, E. M. Sizoo, I. Bosma, F. E. Froklage, J. J. Heimans, T. Postma, J. C. Reijneveld, M. Klein, F. E. Froklage, E. M. Sizoo, M. de Groot, T. J. Postma, M. J. Taphoorn, I. Bosma, L. Oosterbaan, J. C. Reijneveld, J. J. Heimans, L. Douw, M. Klein, J. S. Wefel, T. S. Armstrong, M. Wang, M. Won, A. Bottomley, T. R. Mendoza, C. Coens, M. Werner-Wasik, D. G. Brachman, A. K. Choucair, M. P. Mehta, M. R. Gilbert, M. Otten, C. B. Mikell, B. E. Youngerman, S. A. Small, G. McKhann, I. Slavc, U. Leiss, A. Dressler, A. Peyrl, K. Dieckmann, T. Czech, D. D. Correa, R. Baser, K. Beal, K. Sasan, D. Lisa, K. Panageas, R. Barradas, M. Statucka, L. Abrey, P. Gutin, A. Omuro, R. Robben, B. M. J. Uitdehaag, S. S. A. A. Fagel, M. J. B. Taphoorn, T. J. Postma, J. J. Heimans, M. Klein, K. Gehring, A. M. Sawyer, C. J. Etzel, F. F. Lang, J. S. Wefel, K. Gehring, A. M. Sawyer, C. J. Etzel, F. F. Lang, J. S. Wefel
Journal: Neuro-Oncology (2011)
Pre-metastatic niches: organ-specific homes for metastases
Authors: Héctor Peinado, Haiying Zhang, Irina R Matei, Bruno Costa-Silva, Ayuko Hoshino, Goncalo Rodrigues, Bethan Psaila, Rosandra N Kaplan, Jacqueline F Bromberg, Yibin Kang, Mina J Bissell, Thomas R Cox, Amato J Giaccia, Janine T Erler, Sachie Hiratsuka, Cyrus M Ghajar, David Lyden
Journal: Nature reviews. Cancer (2017)
Prospective randomized phase II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: A study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
Authors: Heike Richly, Luise Maute, Gerhard Heil, Jörn Rüssel, Elke Jäger, Dieter Koeberle, Stefan Fuxius, Karin Weigang-Koehler, Walter Aulitzky, Bernhard Woehrmann, Gernot Georg Hartung, Berta Moritz, Iris Burkholder, Max E. Scheulen, Lothar Bergmann
Journal: Journal of Clinical Oncology (2013)

4035 Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most common malignant tumours, but PDAC is still associated with a poor prognosis in advanced disease with an overall 5-year survival of only about 15%. Therefore there is a need for new treatment strategies. To improve the standard therapy with gemcitabine we initiated a prospective randomized phase-II trial with gemcitabine (GEM) vs. gemcitabine plus sunitinib (SUNGEM) based on data of in vitro trials and phase-I data for the combination treatment. Methods: Patients (N=113) with locally advanced or metastatic PDAC were prospectively randomized to receive gemcitabine alone (GEM) at a dosage of 1000 mg/m² day 1, 8, 15 q28 or to a combination of gemcitabine and sunitinib (SUNGEM) at a dosage of GEM 1000 mg/m² d1+8 and sunitinib 50mg p.o. d1-14, qd21 (based on a phase-I trial). The primary endpoint was progression-free survival (PFS), secondary endpoints were overall survival (OS), time to progression (TTP), overall response rate (ORR) and toxicity. Results: The confirmatory analysis of PFS was based on the ITT population (N=106). The median PFS was 13.3 weeks (95 %-Cl: 10.4-18.1 weeks) in the GEM group and 11.6 weeks in the SUNGEM arm (95 %-Cl: 7.0-18.0 weeks) (one-sided logrank: p=0.74). The 6-month PFS rate was 26.8 % (95 %-Cl: 15.4-39.5 %) in GEM arm and 25.0 % in SUNGEM arm (95 %-Cl: 14.0-37.8 %). The overall response rate was 6.1 % (95 %-Cl: 0.7-20.2 %) in the GEM arm and was a slightly but not significantly higher for the SUNGEM arm with 7.1% (95%-Cl: 0.9 – 23.5%).The median time to progression (TTP) was 14.0 weeks (95 %-Cl: 12.4-22.3 weeks) for the GEM arm and 18.0 weeks (95 %-Cl: 11.3-19.3 weeks) for the SUNGEM arm (two-sided logrank: p=0.60). The median OS was 30.4 weeks (95 %-Cl: 18.1-37.6 weeks) for the SUNGEM and 36.7 weeks (95 %-Cl: 20.6-49.0 weeks) for the GEM arm (two-sided logrank: p=0.44). With regard to toxicities, at least one AE of grade 3 or 4 was reported in 78.8% in the SUNGEM arm and 72.2% in the GEM arm. Conclusions: The combination of gemcitabine plus sunitinib (SUNGEM) did not improve the PFS in locally advanced or metastatic PDAC compared to gemcitabine alone. Clinical trial information: NCT00673504.
Hevylite and Freelite Tests in Newly Diagnosed Multiple Myeloma: Clinical Utility and Correlations with Clinical Features
Authors: Paola Omedé, Valter Redoglia, Monica Astolfi, Alessandra Larocca, Stefano Spada, Luigi Bourlot, Michele Cavo, Maria Teresa Petrucci, Francesco Di Raimondo, Francesca Patriarca, Alessandro Rambaldi, Giuseppe Rossi, Stelvio Ballanti, Barbara Gamberi, Donatella Iolanda Vincelli, Mariella Grasso, Anna Marina Liberati, Paolo Corradini, Pieter Sonneveld, Mario Boccadoro, Antonio Palumbo
Journal: Blood (2016)
IMPACT OF HEREDITARY CAUSES OF THROMBOSIS ON ISCHEMIC STROKE BETWEEN THE YEARS 2008 THROUGH 2012: NATIONWIDE INPATIENT SAMPLE DATA ANALYSIS
Authors: Yashwant Agrawal, Chris Jacob, Carleigh Zahn, Sourabh Aggarwal, Sidakpal Panaich, Frank Saltiel, Jagadeesh Kalavakunta, Vishal Gupta
Journal: Journal of the American College of Cardiology (2017)
NEW MODIFICATION OF ISOMETRIC HANDGRIP STRESS ECHOCARDIOGRAPHY FOR DETECTION OF CORONARY ARTERY DISEASE: COMBINATION OF EXERCISE AND EMOTIONAL STRESS ECHOCARDIOGRAPHY
Authors: Vadim A. Kuznetsov, Dmitriy Krinochkin, Elena Yaroslavskaya, Georgiy Pushkarev, Elena Zakharova
Journal: Journal of the American College of Cardiology (2017)
Prospective Isolation and Functional Characterization of Human Bone Marrow-Derived Hematopoietic Stem Cell-Supportive Mesenchymal Stromal Cells.
Authors: Yoshikazu Matsuoka, Yutaka Sasaki, Masaya Takahashi, Ryusuke Nakatsuka, Yasushi Uemura, Masami Inoue, Hiroyasu Ogawa, Takayuki Takahashi, Jun Ishikawa, Masayuki Hino, Yoshiaki Sonoda
Journal: Blood (2010)
SEX DIFFERENCES IN RISK FACTORS FOR LONGITUDINAL CHANGES IN LEFT VENTRICULAR DIASTOLIC FUNCTION: THE ROTTERDAM STUDY
Authors: Oscar L. Rueda-Ochoa, Marco A. Smiderle Gelain, Jaap Deckers, Dimitris Rizopoulos, Klodian Dhana, Albert Hofman, Oscar H. Franco, Maryam Kavousi
Journal: Journal of the American College of Cardiology (2017)
Hyper-CVAD Plus Nelarabine: A Pilot Study for Patients with Newly Diagnosed T Cell Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LL)
Authors: Stefan Faderl, Deborah A. Thomas, Charles A. Koller, Farhad Ravandi, Jan Burger, Susan O’Brien, Samuel Dara, Hagop M. Kantarjian
Journal: Blood (2008)
Efficacy and safety of neoadjuvant chemotherapy of sequential doublets and dose dense plus trastuzumab in HER2-positive locally advanced breast cancer patients
Authors: E. Grande, A. Sanchez-Muñoz, A. García-Tapiador, A. Ortega-Granados, A. Jaén-Morago, R. Dueñas-García, M. Farnández-Navarro, B. Dueñas, J. Martínez-Ferrol, E. Grande, P. Sánchez-Rovira
Journal: Journal of Clinical Oncology (2007)

11089 Background: Neoadjuvant therapy for breast cancer constitutes an excellent test to evaluate the sensitivity to chemotherapeutic agents and/or new biological agents against specific targets as trastuzumab and Her2. Furthermore, pathologic complete response (pCR) is a surrogate marker for disease-free and overall survival. Methods: The objective was to determine the efficacy in terms of pCR rates and the safety profile of the doublets plus trastuzumab schedule administered for the neoadjuvant setting of locally advanced breast cancer patients. A total of 20 patients with histologically confirmed locally invasive Her2-positive breast carcinoma were included. The median age was 43. Mean tumour size was 5.1 cm. Treatment consisted of a first sequence with epirubicin 90 mg/m2 and cyclophophamide 600 mg/m2 for 3 cycles, and a second sequence with paclitaxel 150 mg/m2 and gemcitabine 2500 mg/m2 for six cycles. All drugs were administered on day 1, every two weeks with prophylactic growth factor supports. Weekly trastuzumab was administered at a dose of 2mg/kg (4 mg/kg loading dose), concomitantly with paclitaxel and gemcitabine. Subsequently, patients underwent surgery and received radiotherapy and/or adjuvant hormonal therapy according to institutional practice Results: Objective clinical response was achieved in all patients. 10 (50%) pCR were obtained. With a median follow up of 18.2 months (3–38), 17 patients (85%) are alive without disease progression, and 3 (15%) showed recurrence and 1 of whom died. Treatment was well tolerated, 1 patient experienced 1 episode of grade 4 neutropenia and 2 patients had grade 3 neutropenia. 1 patient discontinued the treatment due to hypersensitivity reaction to paclitaxel. Asymptomatic decrease in cardiac ejection fraction with subsequent normalization was seen in 1 case. Conclusions: Despite of the small number of patients, results have shown a high pCR rate in this group of breast cancer patients with poor prognostic. The schedule seems to be feasible and tolerable and further studies with the doublet sequences plus trastuzumab are warranted on the neoadjuvant Her2 positive breast cancer patients No significant financial relationships to disclose.
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Authors: Shaji K. Kumar, Natalie S. Callander, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Matthew Faiman, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Michaela Liedtke, Thomas Martin, James Omel, Noopur Raje, Frederic J. Reu, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead, Rashmi Kumar
Journal: Journal of the National Comprehensive Cancer Network (2017)

Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal damage, a hallmark of multiple myeloma. Other MM-related complications include hypercalcemia, renal insufficiency, anemia, and infections. The NCCN Multiple Myeloma Panel members have developed guidelines for the management of patients with various plasma cell dyscrasias, including solitary plasmacytoma, smoldering myeloma, multiple myeloma, systemic light chain amyloidosis, and Waldenström's macroglobulinemia. The recommendations specific to the diagnosis and treatment of patients with newly diagnosed MM are discussed in this article.
Preliminary results of RTOG 0831, a randomized, double-blinded, placebo-controlled trial of tadalafil in the prevention of erectile dysfunction in patients treated with radiotherapy for prostate cancer.
Authors: Deborah Bruner, Stephanie L. Pugh, Thomas Michael Pisansky, Richard Evan Greenberg, Nadeem Pervez, Daniel R. Reed, Seth A Rosenthal, Rex B. Mowat, Adam Raben, Mark K. Buyyounouski, Lisa A. Kachnic
Journal: Journal of Clinical Oncology (2013)

9525 Background: Determine if prophylactic tadalafil maintains spontaneous (off-drug) erectile function (EF) compared to placebo in patients (pts) treated with radiotherapy (RT) for prostate cancer. Methods: Double-blind 1:1 randomization to tadalafil 5mg daily for 6 mos vs placebo starting with RT. Primary outcomes measured by International Index of Erectile Function (IIEF). Eligibility included pre-RT IIEF Question [Q] 1 response “sometimes/most times/always” able to get an erection. Ps treated with hormones were excluded. Primary outcome was response to IIEF Q1 at 30 wks (6 wks off drug). Pts were stratified by RT modality (external vs. brachytherapy) and age (≤65 vs. &gt;65 years). 182 pts were needed in an intent-to-treat analysis to show a difference from 20% responders with placebo to 40% with tadalafil based on a 2-sided Fishers exact test with α=0.05 and 80% power. Results: We report on 155/222 analyzable/eligible pts. Median age was 63 years, white (73%), and external RT (63%). Mean total dose for external RT was 77.23 Gy and 136.74 Gy for brachytherapy with penile bulb D50 of 24.46 Gy and 31.24 Gy respectively. Most pts completed treatment per protocol (84% tadalafil, 70% placebo). Spontaneous EF at 30 wks from drug start was not different (p=0.99) between arms based on IIEF Q1 response, total IIEF score (52.5 drug vs 52.8 placebo), or score change from baseline (-8.0 drug vs -8.8 placebo). No difference in these outcomes was noted at 1 year. Non-responders at 30 wks were likely to be older (age≥65; p=0.432), but there were no significant predictors at 1 year. About 80% of pts maintained spontaneous EF in both arms. Conclusions: Low-dose daily tadalafil did not preserve EF within the first year of RT for prostate cancer. If tadalafil positively influences delayed RT-induced vasogenic injury, additional time may be needed to observe a benefit to tadalafil as a preventive agent. Alternatively, tadalafil dose modification or altered dosing schedules may be needed to demonstrate a protective effect of this agent when used with RT. Clinical trial information: NCT00951184.
MOLECULAR DETERMINANTS OF FUNCTIONAL CHANGES AND FIBROSIS DETERMINED BY NOVEL AUTOMATED OSCILLOMETRIC APPROACH TO MEASURE BRACHIAL ARTERY VASCULAR VOLUME ELASTIC MODULUS IN CHRONIC KIDNEY DISEASE
Authors: Keiichiro Yoshinaga, Yoichi Ito, Satoshi Fujii, Saori Nishio, Noriki Ochi, Katoh Chietsugu, Mamiko Inoue, Mutsumi Nishida, Osamu Manabe, Nagara Tamaki
Journal: Journal of the American College of Cardiology (2017)
Retrospective analysis on patients with male breast cancer
Authors: A. M. Alvarez, M. N. Gandur Quiroga, G. Cinat, J. Iturbe, T. Said Nissi, J. Lacava, V. Cuartero, C. Vallejo, B. Leone, E. Mickiewicz
Journal: Journal of Clinical Oncology (2007)

19681 Background: Male breast cancer is uncommon, 1%(0.7 %)of all breast cancer. Nevertheless, the incidence has climbed 26% over the past 25 years. Objetive: Analyze the form of presentation and clinical evolution of patients with male breast cancer studied from 1977 to 2005. Methods: From 1977 to 2005 53 charts were analyzed: age, clinical presentation, stage (st), histological characteristics and nodal involvement. Results: Age: 33 years to 83 years (median= 59 years). Mean durations of symptoms before presentations: 11 months (m) (range 1 - 84 m.) . Forty-six (86.7%) patients (pts) had history of breast lumps, 9 (17%) were painful. Skin involvement and ulceration were present in 5 (9.43%) and 4 (7.54 %) respectively. One case of bilateralism was found. Seven (13.2%) st. I; 18 (33.96%) st. II; 20 (37.73%) st. III and 7 (13.2%) st. IV. Radical mastectomy was done in 41 pts (77.35%). Invasive ductal carcinoma was the most common histological type in 45 (84.9%). One case of lobular carcinoma was found. 60.4% of tumours expressed hormonal receptor. Adyuvant treatment: Adriamycin-based chemotherapy in 20 pts and CMF in 8 pts. Hormonotherapy was offered in 10 (19%) pts of the previous group, radiotherapy to 12 pts. twenthy pts (37.73%) presented recurrence; most common was bone in 10. The st. I and II estimated 5-year survival rate was 68% IC 95% (44–84%), st. III was 44% IC 95% (23 - 67%), st. IV (median = 24 m) with range (16 - 56 m). The 72% IC 95% (48–88%) patients st. I and II was free of disease at the 5-years, st. III was free 24% IC 95% (9–49%), st. IV (median = 7,5 m) with range (7–14 m). Conclusions: The media age at diagnosis was 59 years (10 years less than the international bibliography). (IB). Our group had longer time to presentation: 11 vs. 6 m., (IB) and most of them where in st. III. Hormonal receptore were positive in 60%. No significant financial relationships to disclose.
Vitamin K2 Supports Hematopoiesis through Acting on Bone Marrow Mesenchymal Stromal/Stem Cells
Authors: Aya Fujishiro, Yasuo Miura, Masaki Iwasa, Sumie Fujii, Akihiro Tamura, Atsushi Sato, Asumi Yokota, Noriko Sugino, Hideyo Hirai, Akira Ando, Tatsuo Ichinohe, Taira Maekawa
Journal: Blood (2015)
RETHINKING THE ROLE OF CORONARY ANGIOGRAPHY IN THE EVALUATION OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN YOUNG PATIENTS
Authors: John Hollowed, Pooya Banankhah, Carmen Flores, Mario Roman, Grecia Marquez, Gracia Viana, Juan Sequeira Gross, Juani Nieto, Ronney Shantouf
Journal: Journal of the American College of Cardiology (2017)
Corrleation of health-related quality of life (HRQL) of cancer patients and the mental component parameters of their family members
Authors: I. Vrettos, A. Papadopoulos, K. Kamposioras, D. Charitos, G. Giannopoulos, D. Pectasides, D. Niakas, T. Economopoulos
Journal: Journal of Clinical Oncology (2009)

e20619 Background: It is widely experienced that health-related quality of life (HRQL) is greatly influenced in the family members of cancer patients. The aim of this study was to find the correlation of the HRQL parameters in cancer patients with the main mental component parameters of patients’ relatives. Methods: 122 cancer patients undergoing chemotherapy in our department (49 men and 73 women) of mean age 56.6 ±15.4 1SD and their 122 relatives that accompanied them (45 men and 77 women) of mean age 48.3 ±14.5 completed the validated SF-36 health survey by personal interview. The SF-36 health survey summarizes the functional health status and general health into eight scales with higher scores (0–100 range) reflecting better-perceived health. In this study, physical functioning (PF), role physical (RP), bodily pain (BP), general health perception (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MH) of the patients were correlated with the SF, RE, MH of their family members using the Spearman's test. Data analysis was performed with SPSS version 13.0 and correlations were considered statistically significant when p&lt;0.05. Results: Table 1 summarizes the results of our study. Social Functioning and Mental Health of family members are highly correlated with the HRQL parameters of cancer patients. The RE does not seem to be affected. Conclusions: HRQL of cancer patients undergoing chemotherapy is highly correlated with the SF and the MH of their relatives. This observation highlights the need to develop more oriented supportive programs for both the patients and their family memebers. Abbreviations: PF = Physical Functioning, RP = Role Physical, BP = Bodily Pain, GH = General Health, VT = Vitality, SF = Social Functioning, RE = Role Emotional, MH = Mental Health; NS=Not Significant. * = 0.05. ** = 0.01. [Table: see text] No significant financial relationships to disclose.
C1 neurons mediate a stress-induced anti-inflammatory reflex in mice
Authors: Chikara Abe, Tsuyoshi Inoue, Mabel A Inglis, Kenneth E Viar, Liping Huang, Hong Ye, Diane L Rosin, Ruth L Stornetta, Mark D Okusa, Patrice G Guyenet
Journal: Nature Neuroscience (2017)
One in 20 patients has gambling problems, UK study finds
Authors: Susan Mayor
Journal: BMJ (2017)

Around one in 20 adults has problems with gambling, a UK general practice study has found. The authors call for increased resources for recognising and responding to gambling problems in primary care.

Gambling problems are associated with deprivation, anxiety disorders, psychosomatic complaints, and high rates of suicidal ideation and attempts. But there has previously been little information on how to identify patients who might benefit from help.

Researchers recruited 1058 adult …
HLA Homozygosity and Haplotype Bias Among Patients with Chronic Lymphocytic Leukemia: Implications for Disease Control by Physiologic Immune Surveillance
Authors: Nina Shah, William Decker, Ruth Lapushin, Dongxia Xing, Simon Robinson, Hong Yang, Simrit Parmar, Shawndeep Tung, Susan O'Brien, Marcelo Fernandez-Vina, Elizabeth J. Shpall, William G. Wierda
Journal: Blood (2010)
ENDOVASCULAR CAROTID BAROSTIMULATION FOR RESISTANT HYPERTENSION: A SAFETY AND PROOF-OF-PRINCIPLE COHORT STUDY
Authors: Wilko Spiering, Jan Van der Heyden, Abraham Kroon, Anton van den Meiracker, Chandan Devireddy, Malcolm Foster III, Magdi Ghali, Farrell Mendelsohn, Hannes Reuter, John Reilly, Mark Bates
Journal: Journal of the American College of Cardiology (2017)
COUNTERING THE ANTI-PLATELET EFFECTS OF TICAGRELOR WITH PLATELET CONCENTRATES WITHIN 48 HOURS OF A LOADING DOSE: EX VIVO TESTING OF TIME-EFFECT ON FUNCTIONAL RECOVERY IN PATIENTS WITH CARDIOVASCULAR DISEASE
Authors: Mohammad Urooj Zafar, Donald Smith, Usman Baber, Samantha Sartori, Gines Escolar, Valentin Fuster, Juan Badimon
Journal: Journal of the American College of Cardiology (2017)
Overexpression of the human hyperplastic discs protein EDD is an independent predictor of relapse in serous epithelial ovarian cancer
Authors: D. I. Quinn, M. J. Davies, S. M. Henshall, V. Heinzelmann-Schwarz, C. K. W. Watts, R. L. Sutherland, N. F. Hacker, P. M. O'Brien
Journal: Journal of Clinical Oncology (2004)

5057 Background: EDD is the human orthologue of the Drosophila hyperplastic discs tumor suppressor gene that encodes a HECT domain E3 ubiquitin protein ligase and may have a role in DNA repair as well as protein degradation. It is amplified and over-expressed in a variety of cancers including serous epithelial ovarian cancer (SOC) (Clancy JL et al. Oncogene 22: 5070, 2003). In this study we sought to determine the prognostic potential of EDD protein (EDDp) expression in SOC. Methods: Using immunohistochemistry on tissue microarrays, we examined EDDp expression in 154 cases of SOC treated with surgical debulking and adjuvant chemotherapy. Expression was correlated with clinicopathological parameters and patient outcome. Results: Median follow-up time was 28 months; median survival was 28 months. Increased EDDp expression correlated with preoperative CA125 level (p=0.025) and relapse (p=0.02) but not FIGO stage, grade, age, residual disease, PS or menopausal status. Univariate predictors of relapse-free survival were stage, volume of residual disease >2cm and EDDp, all of which remained significant in multivariate analysis. Univariate predictors of overall survival were stage, grade, PS and residual disease but not EDDp (p=0.17) while in multivariate analysis grade became non-significant (p=0.06). The effect of EDDp on outcome did not vary based on the type of adjuvant chemotherapy received (platinum, taxane or alkylating agents). Conclusions: EDDp over-expression independently predicted time to relapse but not overall survival in SOC. This observation deserves further evaluation with longer follow-up in our cohort and others. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aventis